- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00005983
S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes Phase III
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether mastectomy, chemotherapy, and/or hormone therapy are more effective with or without radiation therapy in treating breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of mastectomy, chemotherapy, and/or hormone therapy with or without radiation therapy in treating women who have stage II breast cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Compare overall and disease-free survival in women with stage II breast cancer with one to three positive nodes treated with radiotherapy vs observation only after mastectomy and adjuvant chemotherapy and/or hormonal therapy.
- Compare local regional control in patients treated with these regimens.
- Assess the potential toxic effects of radiotherapy in this patient population.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prior systemic hormonal therapy (chemotherapy with or without hormonal therapy vs hormonal therapy alone), prior taxane exposure (yes vs no), and duration of chemotherapy (no chemotherapy vs less than 3 months vs 3-5 months vs 6 months or more). Patients are randomized to one of two treatment arms.
- Arm I: Patients undergo radiotherapy 5 days a week for 5 weeks.
- Arm II: Patients are observed for disease progression. Patients are followed every 6 months for 2 years and then annually for 15 years.
PROJECTED ACCRUAL: A total of 2,500 patients (1,250 per treatment arm) will be accrued for this study within 5 years.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Cancer Care Ontario-Hamilton Regional Cancer Centre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Histologically confirmed stage II adenocarcinoma of the breast (T1-2, N1, M0)
- Primary tumor no greater than 5 cm
- At least 1 but no more than 3 positive axillary lymph nodes
- Nodes cannot be positive solely by cytokeratin staining
- No apocrine, adenocystic, or squamous cell carcinomas or sarcomas of the breast
- No bilateral breast cancer
- No active local regional disease
Must have undergone a modified radical mastectomy with a level I and II with or without a level III axillary dissection (at least 10 nodes examined) within the past 8 months
- Surgical margins negative for invasive and noninvasive ductal carcinoma
- No gross extracapsular disease or residual disease in the axilla
- Microscopic extracapsular extension allowed
- No mastectomy after local failure following lumpectomy
- Must have received adjuvant chemotherapy and/or hormonal therapy after mastectomy
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- 21 and over
Sex:
- Female
Menopausal status:
- Pre- or post-menopausal
Performance status:
- Zubrod 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No serious medical or psychiatric illness that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior trastuzumab (Herceptin)
Chemotherapy:
- See Disease Characteristics
- No more than 6 weeks since prior adjuvant chemotherapy
- No other prior chemotherapy
- Concurrent adjuvant chemotherapy allowed
Endocrine therapy:
- See Disease Characteristics
- Concurrent adjuvant hormonal therapy allowed
Radiotherapy:
- No prior chest wall or nodal radiotherapy
Surgery:
- See Disease Characteristics
- Breast reconstruction allowed
Other:
- Concurrent registration on another adjuvant chemotherapy or hormonal therapy study is allowed
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: surgery
surgery followed by observation
|
chirurgie
|
|
Expérimental: surgery followed by RT
Surgery followed by radiation therapy
|
chirurgie
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Timothy J. Whelan, MD, Margaret and Charles Juravinski Cancer Centre
- Chaise d'étude: Lori J. Pierce, MD, University of Michigan Rogel Cancer Center
- Chaise d'étude: Stephen B. Edge, MD, Roswell Park Cancer Institute
- Chaise d'étude: Eric A. Strom, MD, FACR, M.D. Anderson Cancer Center
- Chaise d'étude: Lawrence J. Solin, MD, FACR, Abramson Cancer Center of the University of Pennsylvania
- Chaise d'étude: Lawrence B. Marks, MD, Duke University
- Chaise d'étude: Melvin Deutsch, MD, UPMC Cancer Center at UPMC Presbyterian
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CDR0000067971
- U10CA032102 (Subvention/contrat des NIH des États-Unis)
- S9927 (Autre identifiant: NSABP)
- CAN-NCIC-MA25 (Autre identifiant: NCIC-CTG)
- CLB-49910 (Autre identifiant: CALGB)
- RTOG-9915 (Autre identifiant: RTOG)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .